X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
INNA-051 is a TLR2/6 agonist, small molecule drug candidate in development as an innate immune modulator, delivered using a nasal spray. It is being evaluated for the treatment of Influenza.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
INNA-051 is a potent TLR2/6 agonist that is delivered using a convenient nasal spray to target the preferential site of initial replication of viral respiratory infections.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
The funding will support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator for the prevention of complications associated with respiratory viral infections in at-risk populations.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $8.1 million Upfront Cash: Undisclosed
Deal Type: Funding August 29, 2023
Details:
INNA-051 is a broad-spectrum antiviral immunomodulatory nasal spray under clinical development for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of severe complications.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
INNA-051 is a potent innate immune TLR2/6 agonist. It is currently in clinical development for self-administered intranasal delivery to target the primary entry site of viral respiratory infections as most respiratory viruses, including SARS-CoV-2 and influenza.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $4.3 million Upfront Cash: Undisclosed
Deal Type: Funding January 09, 2023
Details:
Pre-clinical research demonstrates that INNA-051 has pan-antiviral potential with efficacy against a variety of respiratory viruses, including SARS-CoV-2, influenza, and the common cold rhinovirus.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blue Knight
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, a potent innate immune TLR2/6 agonist, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
The partnership adds INNA-051 to the COPD Foundation’s COPD360Net® pipeline and will utilize its global network of accredited centres, scientific expertise, and patient investigators to optimize and accelerate the clinical development program.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: COPD Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 23, 2022
Details:
The self-administered nasal spray, INNA-051, is being developed to stimulate the innate immunity in the nose, where most respiratory viral infections begin. INNA-051 is a potent innate immune agonist that targets the receptor TLR2/6.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
The new financing will advance INNA-051, ENA Respiratory’s lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Brandon Capital
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
